Seladelpar improves key liver function markers in PBC
A relatively new therapy, seladelpar, has an acceptable efficacy and safety profile in the treatment of PBC.
A relatively new therapy, seladelpar, has an acceptable efficacy and safety profile in the treatment of PBC.
Close monitoring and early intervention may help mitigate disease progression in high-IgG patients with PBC.
Patients diagnosed with primary biliary cholangitis (PBC), particularly those who also develop cirrhosis, face frequent hospital visits and high medical costs, found a study published recently in the Journal of Comparative Effectiveness Research. Analyzing two large healthcare databases from 2015 to 2023, researchers discovered that among patients who experienced at least one hospitalization or emergency […]
A recent study found that while all second-line treatments for PBC improved liver test results, the drugs have differences in effectiveness and side effects.
AIH-PBC overlap syndrome is a rare autoimmune liver disease requiring early diagnosis and treatment to prevent complications.
The FDA gave volixibat a special approval as a potential treatment for itching in patients with primary biliary cholangitis.
A new study suggests which method is superior for detecting genetic variables associated with primary biliary cholangitis (PCB).
A recently published case report described a pregnant patient diagnosed with PBC, hypertension and preeclampsia.
Results were positive from a 120-day phase 2a study of CNP-104, a proposed treatment for primary biliary cholangitis.
In a recent study, patients with PBC experienced more muscle loss, itching and malnutrition than patients with other liver disorders.